{"title":"New insights into Th9 cells in inflammatory bowel diseases","authors":"Markus F. Neurath","doi":"10.1016/j.smim.2025.102013","DOIUrl":null,"url":null,"abstract":"<div><div>The involvement of T helper cells in the pathogenesis of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, has been a subject of considerable research interest. The clinical picture of IBD is characterised by chronic intestinal inflammatory processes that may lead to complications such as stenoses, abscesses, fistulas and colorectal cancer. Recent findings have indicated that T helper 9 (Th9) cells, which secrete the cytokine IL-9, play a role in the pathogenesis of IBD. These cells have been observed to damage the intestinal epithelium by IL-9 production and to amplify the mucosal inflammatory immune response by activating other immune cells. Studies utilising murine models of chronic intestinal inflammation have demonstrated that targeting IL-9 or Th9 cells can alleviate inflammatory responses. In consideration of these findings, it will be of interest to delve into the potential of neutralizing IL-9 function as a therapeutic intervention for patients suffering from IBD.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"81 ","pages":"Article 102013"},"PeriodicalIF":11.5000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1044532325000855","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The involvement of T helper cells in the pathogenesis of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, has been a subject of considerable research interest. The clinical picture of IBD is characterised by chronic intestinal inflammatory processes that may lead to complications such as stenoses, abscesses, fistulas and colorectal cancer. Recent findings have indicated that T helper 9 (Th9) cells, which secrete the cytokine IL-9, play a role in the pathogenesis of IBD. These cells have been observed to damage the intestinal epithelium by IL-9 production and to amplify the mucosal inflammatory immune response by activating other immune cells. Studies utilising murine models of chronic intestinal inflammation have demonstrated that targeting IL-9 or Th9 cells can alleviate inflammatory responses. In consideration of these findings, it will be of interest to delve into the potential of neutralizing IL-9 function as a therapeutic intervention for patients suffering from IBD.
期刊介绍:
Seminars in Immunology is a specialized review journal that serves as a valuable resource for scientists in the field of immunology. The journal's approach is thematic, with each issue dedicated to a specific topic of significant interest to immunologists. It covers a wide range of research areas, from the molecular and cellular foundations of the immune response to the potential for its manipulation, highlighting recent advancements in these areas.
Each thematic issue is curated by a guest editor, who is recognized as an expert in the field internationally. The content of each issue typically includes six to eight authoritative invited reviews, which delve into various aspects of the chosen topic. The goal of these reviews is to provide a comprehensive, coherent, and engaging overview of the subject matter, ensuring that the information is presented in a timely manner to maintain its relevance.
The journal's commitment to quality and timeliness is further supported by its inclusion in the Scopus database, which is a leading abstract and citation database of peer-reviewed literature. Being indexed in Scopus helps to ensure that the journal's content is accessible to a broad audience of researchers and professionals in immunology and related fields.